US OptionsDetailed Quotes

AFYA241220P10000

Watchlist

0.00
0.000.00%

15min DelayClose Dec 20 09:30 ET

0.00High0.00Low

Afya Ltd Stock Discussion

Moomoo AI

Mar 17 09:51

The stock is undervalued and its bright future isn't fully reflected in the current price, indicating a potential buying opportunity. However, consider other factors like capital structure before investing.

Is It Too Late To Consider Buying Afya Limited (NASDAQ:AFYA)?

Moomoo AI

Jan 3 08:48

Afya exhibits robust financials, boasting a good ROE and extraordinary net income growth exceeding industry norms. The company's effective reinvestment of profits might contribute to the high earnings growth. Analysts predict a future acceleration in Afya's earnings.

Is Afya Limited's (NASDAQ:AFYA) Latest Stock Performance A Reflection Of Its Financial Health?

Moomoo AI

Oct 27, 2023 05:42

Shareholders may consider selling Afya stocks given the current valuation, expecting to buy back at lower prices. Despite Afya's positive outlook, the hefty price tag indicates that its future growth may already be priced in.

What Is Afya Limited's (NASDAQ:AFYA) Share Price Doing?

Bull Market Watch

Jun 22, 2023 01:38

This Stock Has Powerful Momentum | High Growth Ahead | Stock To Buy

$Afya Ltd (AFYA.US)$

This Stock Has Powerful Momentum | High Growth Ahead | Stock To Buy

From YouTube

Analysts Notebook

Apr 8, 2022 06:38

Columns Top upgrades and downgrades on 4/8

Upgrades
• $Afya Ltd (AFYA.US)$: Credit Suisse Upgrades to Outperform from Neutral - PT $19 (from $18)
• $Appfolio (APPF.US)$: KeyBanc Upgrades to Overweight from Sector Weight - PT $143
• $C.H. Robinson Worldwide (CHRW.US)$: JPMorgan Upgrades to Overweight from Neutral - PT $117 (from $91)
• $Coupang (CPNG.US)$: Goldman Sachs Upgrades to Conviction Buy from Buy - PT $37
• $Gatos Silver (GATO.US)$: RBC Capital Upgrades to Sector Perform from Underperform - PT $4
• $ITT Inc (ITT.US)$: UBS Upgr...

Moomoo Breakfast US

Apr 6, 2022 07:42

Columns Today's pre-market stock movers: ARRY, RIOT, MRNA, NVAX and more

Gainers:
• $Array Technologies (ARRY.US)$ +12.87% (also names new CEO)
• $Tufin Software Technologies (TUFN.US)$ +43.41% (enters into definitive agreement to be acquired by Turn/River Capital in a $570 million transaction; TUFN shareholders will receive $13.00/share in cash)
• $Citius Pharmaceuticals (CTXR.US)$ +10.87% (reported topline results from the pivotal Phase 3 trial of I/ONTAK)
• $BioXcel Therapeutics (BTAI.US)$ +19.22% (FDA ha...

No comment yet